Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study successfully completed demonstrating strong safety and a 67% Complete Response (“CR”) rate for patients treated at the therapeutic dose.
In-progress pivotal Phase II NMIBC clinical study under since November 2020.
Patented light-activated Photo Dynamic Compounds ("PDCs") have been scientifically and preclinically researched for 18+ years to optimize their ability to destroy cancer, bacteria and viruses.
Over 10+ peer reviewed published research publications.
Secondary: Non-Small Cell Lung Cancer ("NSCLC") , GlioBlastoma Multiforme ("GBM"), Vaccine for various enveloped viruses.
TMX Equity Transfer Services Inc.
100 Adelaide Streety West, Suite 301,
M5H 1S3, CANADA
181 Bay Street, Suite 3510
Bay Wellington Tower
M5J 2T3, CANADA
Chief Financial Officer/Investor Relations
Kristina Hachey, CPA
Theralase Technologies Inc.
41 Hollinger Road,
M4B 3G4, CANADA
Work: 416-699-5373 ext. 224
Data last updated on June 27, 2022
- TSX Venture Exchange (TSXV: TLT)
- Over-The-Counter Exchange (OTCQB: TLTFF)
Share Price: C$0.345
Market Capital: $CAN 70.9 M
Shares Outstanding: 204,425,875
Stock Options: 10,440,000
For Investor Relations please contact: Investor Information Theralase®